Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04739280 · ClinicalTrials.gov registry record
Women's Assessed Cardiovascular Evaluation With MCG
A clinical trial, sponsored by Genetesis.
- Completed
- Registry status
- 32
- Enrollment target
NCT04739280: Completed study, sponsored by Genetesis.
NCT04739280 is a clinical trial that has completed, run by Genetesis. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04739280 has completed, sponsored by Genetesis.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
Cardiovascular disease (CVD) is the number one cause of death for women over the age of 25, accounting for 1 of every 3 female deaths. Research has shown that while hypertension in women is less controlled, they are also less likely to be identified with ischemic heart disease and when diagnosed treated less aggressively than men. Moreover, women who are diagnosed with breast cancer have an increased risk for cardiovascular disease. The Women's Assessed Cardiovascular Evaluation with MCG (WACE-MCG) study is designed to collect CardioFlux scans on a select group of female volunteers who are Ms. Medicine patients. CardioFlux is used as a noninvasive MCG tool that analyzes and records the magnetic fields of the heart to detect various forms of heart disease. There will be a 12-month duration of the study where we propose to collect screening data from approximately 200 volunteers who present to the Genetesis facility for a 5-minute CardioFlux MCG scan. The volunteers will be contacted at intervals over a 1-year period for follow-up data and may choose whether or not they would like to provide follow-up data or participate in another scan.
Primary Outcome
analyzing the accuracy of CardioFlux
Interventions
- DEVICE CardioFlux Magnetocardiography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2022-07-21 |
What the finished NCT04739280 record still lists
NCT04739280 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CardioFlux Magnetocardiography is the first listed.
NCT04739280 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04739280 about?
NCT04739280 is a clinical study titled "Women's Assessed Cardiovascular Evaluation With MCG". Cardiovascular disease (CVD) is the number one cause of death for women over the age of 25, accounting for 1 of every 3 female deaths. Research has shown that while hypertension in women is less controlled, they are also less likely to be identified with ischemic heart disease and when diagnosed tre...
What is the current status of trial NCT04739280?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2020-10-15. Estimated completion is 2022-07-21.
What interventions are being tested in trial NCT04739280?
The interventions under investigation include: CardioFlux Magnetocardiography (DEVICE).
Who is sponsoring clinical trial NCT04739280?
This trial is sponsored by Genetesis, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI